Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Long-Term Deferred Tax (2020 - 2021)

Updated

Grace Therapeutics (GRCE) recorded Long-Term Deferred Tax of $28.64 million in fiscal Q4 2021 (quarter ended Mar 31, 2021), down 6.0% from $30.46 million a year earlier.

Analysis

Grace Therapeutics (GRCE) Long-Term Deferred Tax (2020 - 2021) Analysis & Trends

  • Across earlier fiscal years, Long-Term Deferred Tax came in at $30.46 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 28.64 Mn
Mar 31, 2020 30.46 Mn
API Access

Grace Therapeutics Long-Term Deferred Tax API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-deferred-tax&ticker=GRCE&period=max&api_key=YOUR_API_KEY